Athersys, Inc. (ATHXQ)

0.0048 +0.0002 (+4.35%) At close: 03:55PM EDT

Athersys, Inc.

3201 Carnegie Avenue
Cleveland, OH 44115-2634
United States
216 431 9900
https://www.athersys.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 24

Key Executives

Name	Title	Pay	Exercised	Year Born
Ms. Z. Kasey Rosado	Interim CFO & Director	1.51M	N/A	1974
Senthil Ranganathan Ph.D.	Vice President of Technical Operations	N/A	N/A	N/A
Mr. David Russ M.B.A.	Vice President of Supply Chain, Finance & Administration	N/A	N/A	N/A
Dr. Manal Morsy M.B.A., M.D., PH.D.	Executive VP & Head of Global Regulatory Affairs	N/A	N/A	N/A
Dr. Robert Mays Ph.D.	Executive VP, Head of Regenerative Medicine & Neuroscience Programs	N/A	N/A	N/A
Mr. Rakesh Ramachandran MS	Head of Information Technology & Communications and VP	N/A	N/A	N/A
Dr. Sarah Busch Ph.D.	VP of Regenerative Medicine & Head of Business Development	N/A	N/A	N/A
Ms. Ellen Gurley	Manager of Corporate Communications and Investor Relations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio. On January 5, 2024, Athersys, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Ohio.

Corporate Governance

Athersys, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.